Source:http://linkedlifedata.com/resource/pubmed/id/12503280
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2002-12-30
|
pubmed:abstractText |
There is a disclosure of the results of one-week eradication therapy (esomeprazole, 20 mg + Flemoxin Solutab, 1,000 mg + Clarithromycin, 500 mg, twice a day) without any subsequent antisecretory therapy. In order to control the healing of non-complicated ulcers of the duodenal bulb, the first control endoscopy (esophagogastroduodenoscopy) was conducted after 7 days, and the second one was conducted 4 weeks after the termination of patients' treatment. The healing of ulcers of the duodenal bulb was recorded in 89.5% and 89.5% of cases, respectively. A control determination of the H. pylori semination of the mucous coating of stomach was accomplished 4 weeks after the termination of patients' treatment. According to the data of the fast urease test and 13C-urease respiratory test, the HP eradication was recorded in all of the patients (100%), and according to the data of the histologic method of target biopsy materials studies, it was recorded in 94.7% of cases. A pharmacoeconomic analysis of the acquired data showed that the seven-day eradication therapy of non-complicated duodenal ulcer, where esomeprazole was used as the basic preparation, is most efficient and most economically expedient.
|
pubmed:language |
rus
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amoxicillin,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Ulcer Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Clarithromycin,
http://linkedlifedata.com/resource/pubmed/chemical/Omeprazole,
http://linkedlifedata.com/resource/pubmed/chemical/Penicillins
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1682-8658
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
61-4, 133
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12503280-Adult,
pubmed-meshheading:12503280-Amoxicillin,
pubmed-meshheading:12503280-Anti-Bacterial Agents,
pubmed-meshheading:12503280-Anti-Ulcer Agents,
pubmed-meshheading:12503280-Clarithromycin,
pubmed-meshheading:12503280-Cost-Benefit Analysis,
pubmed-meshheading:12503280-Drug Administration Schedule,
pubmed-meshheading:12503280-Duodenal Ulcer,
pubmed-meshheading:12503280-Female,
pubmed-meshheading:12503280-Helicobacter Infections,
pubmed-meshheading:12503280-Helicobacter pylori,
pubmed-meshheading:12503280-Humans,
pubmed-meshheading:12503280-Male,
pubmed-meshheading:12503280-Middle Aged,
pubmed-meshheading:12503280-Omeprazole,
pubmed-meshheading:12503280-Penicillins
|
pubmed:year |
2002
|
pubmed:articleTitle |
[Pharmacoeconomic aspects of the 1-week eradication treatment of duodenal ulcer associated with Helicobacter pylori].
|
pubmed:affiliation |
Central Scientific Research Institute of Gastroenterology, Moscow.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract
|